BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maleux G, van Malenstein H, Vandecaveye V, Heye S, Vaninbroukx J, Nevens F, Verslype C. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Dig Dis. 2009;27:157-163. [PMID: 19546554 DOI: 10.1159/000218348] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Higgins LJ, Hwang GL, Rosenberg J, Katzenberg RH, Kothary N, Sze DY, Hofmann LV. In Vitro Design and Characterization of the Nonviral Gene Delivery Vector Iopamidol, Protamine, Ethiodized Oil Reagent. Journal of Vascular and Interventional Radiology 2011;22:1457-1463.e2. [DOI: 10.1016/j.jvir.2011.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
2 Chen CS, Li FK, Guo CY, Xiao JC, Hu HT, Cheng HT, Zheng L, Zong DW, Ma JL, Jiang L, Li HL. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Oncotarget 2016;7:7241-52. [PMID: 26769845 DOI: 10.18632/oncotarget.6892] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
3 Dekervel J, van Malenstein H, Vandecaveye V, Nevens F, van Pelt J, Heye S, Laleman W, Van Steenbergen W, Vaninbroukx J, Verslype C, Maleux G. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up. J Vasc Interv Radiol 2014;25:248-55.e1. [PMID: 24295569 DOI: 10.1016/j.jvir.2013.10.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
4 Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:1343-1350. [PMID: 22486716 DOI: 10.1111/j.1365-2036.2012.05089.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
5 Jiang G, Ling S, Zhan Q, Zhuang L, Xu X. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplant Rev (Orlando) 2021;35:100606. [PMID: 33636480 DOI: 10.1016/j.trre.2021.100606] [Reference Citation Analysis]
6 Chen HY, Wang Y, Li Q. Advances in research of microspheres containing Chinese medicine for interventional cancer therapy. Shijie Huaren Xiaohua Zazhi 2010; 18(22): 2350-2354 [DOI: 10.11569/wcjd.v18.i22.2350] [Reference Citation Analysis]
7 Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol. 2011;197:W562-W570. [PMID: 21940527 DOI: 10.2214/ajr.10.4379] [Cited by in Crossref: 109] [Cited by in F6Publishing: 45] [Article Influence: 9.9] [Reference Citation Analysis]
8 Chok KS, Cheung TT, Lo RC, Chu FS, Tsang SH, Chan AC, Sharr WW, Fung JY, Dai WC, Chan SC. Pilot study of high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients wait-listed for liver transplantation. Liver Transpl. 2014;20:912-921. [PMID: 24753206 DOI: 10.1002/lt.23892] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
9 Kong JY, Li SM, Fan HY, Zhang L, Zhao HJ, Li SM. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e11872. [PMID: 30113483 DOI: 10.1097/MD.0000000000011872] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Xia JZ, Xie FL, Ran LF, Xie XP, Fan YM, Wu F. High-intensity focused ultrasound tumor ablation activates autologous tumor-specific cytotoxic T lymphocytes. Ultrasound Med Biol. 2012;38:1363-1371. [PMID: 22633269 DOI: 10.1016/j.ultrasmedbio.2012.03.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ghanaati H, Alavian SM, Jafarian A, Ebrahimi Daryani N, Nassiri-Toosi M, Jalali AH, Shakiba M. Imaging and Imaging-Guided Interventions in the Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence. Iran J Radiol. 2012;9:167-177. [PMID: 23407596 DOI: 10.5812/iranjradiol.8242] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
12 Heinzow HS, Meister T, Nass D, Köhler M, Spieker T, Wolters H, Domschke W, Domagk D. Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol 2011;46:201-10. [PMID: 20969491 DOI: 10.3109/00365521.2010.525256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
13 She WH, Cheung TT. Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol. 2016;1:34. [PMID: 28138601 DOI: 10.21037/tgh.2016.03.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
14 Wang SH, Chen LM, Yang WK, Lee JD. Increased extrinsic apoptotic pathway activity in patients with hepatocellular carcinoma following transarterial embolization. World J Gastroenterol 2011; 17(42): 4675-4681 [PMID: 22180709 DOI: 10.3748/wjg.v17.i42.4675] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
15 Firouznia K, Ghanaati H, Alavian SM, Azadeh P, Nasiri Toosi M, Haj Mirzaian A, Najafi S, Shakiba M, Jalali AH. Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma. Hepat Mon 2014;14:e25792. [PMID: 25737732 DOI: 10.5812/hepatmon.25792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
16 Lee JH, Park KM, Lee YJ, Kim JH, Kim SH. A New Chemical Compound, NecroX-7, Acts as a Necrosis Modulator by Inhibiting High-Mobility Group Box 1 Protein Release During Massive Ischemia-Reperfusion Injury. Transplant Proc 2016;48:3406-14. [PMID: 27931589 DOI: 10.1016/j.transproceed.2016.09.046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]